Latest News
CVS Health declares unchanged quarterly dividend
1 October 2026 - US healthcare company CVS Health (NYSE:CVS) announced on Wednesday that its board of directors has approved a quarterly dividend of USD0.665 per share on its common stock.This amount is unchanged from the previous quarterly dividend....
Fresenius acquires remaining stake in mAbxience
1 October 2026 - Biotechnology company mAbxience announced on Thursday that German healthcare company Fresenius SE & Co KGaA has acquired the remaining 45% of mAbxience from Insud Pharma, building on the successful partnership established between...
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
30 September 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) revealed on Wednesday that it has achieved positive 48-week Phase 2b results for EloraTZP, its investigational combination of eloralintide and tirzepatide, showing greater weight ...
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
30 September 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Wednesday announced positive Phase 2b results for tulisokibart, an investigational anti-TL1A monoclonal antibody, in patients with...
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
30 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for fenebrutinib under priorit...